Board / shareholder meeting outcomeFiled on BSE ·
Trident Lifeline Limited issues corrigendum to EGM notice for preferential issue
Trident Lifeline Ltd · Pharmaceuticals & Biotechnology
What the filing says
- Board approved issuance of corrigendum to EGM notice as per stock exchange instructions
- Preferential issue: 12,22,200 equity shares to non-promoter/public and 5,00,400 warrants to promoter/non-promoter
- Revised utilization of proceeds: ₹41.14 crore (working capital, investments, expansions) with timelines and UBO details updated
Original filing
Board Meeting Outcome for Outcome Of Board Meeting Held On 16.10.2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Trident Lifeline Ltd
- Board / shareholder meeting outcomeTrident Lifeline Limited issues corrigendum for EGM notice and proposes preferential issue
Other board / shareholder meeting outcome filings this fortnight
- Board / shareholder meeting outcomeRegency FincorpRegency Fincorp Limited approves preferential issue and ESOP, sets EGM
- Board / shareholder meeting outcomeRegency FincorpRegency Fincorp Limited approves preferential issue and ESOP, schedules EGM
- Board / shareholder meeting outcomeRegency FincorpRegency Fincorp Limited approves preferential issue and ESOP; EGM scheduled Nov 11, 2026
- Board / shareholder meeting outcomeString Metaverse LtdString Metaverse Limited holds EGM approving preferential equity shares issue
- Board / shareholder meeting outcomeSahana Systems LtdSahana System Limited files Postal Ballot Notice for preferential equity warrants issue
- Board / shareholder meeting outcomeYatharth Hospital & Trauma Care Services LtdYatharth Hospital & Trauma Care Services Ltd announces EGM voting results dated Oct 15, 2026
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.